{
    "symbol": "ICCM",
    "quarter": 3,
    "year": 2022,
    "date": "2022-12-05 10:20:29",
    "content": " For example, we are using forward-looking statement in this presentation when we discusses pursuit of regulatory approvals in various jurisdictions, strategic plans, commercial growth, expansion of clinical applications release of results from our clinical trials, potential market adoption and future sales of IceCure's minimally-invasive cryoablation technology, advancing regulatory and commercial strategies and expected quarter-over-quarter revenue variations and other key business and operational highlights for future periods. In Brazil, ProSense cryoprobes and introducers, which are essential single use disposable components of our ProSense system received regulatory approval for indications including breast and other cancers, benign tumors and palliative interventions. For the nine months ended September 30, 2022, revenue decreased by 22% to approximately $2.1 million compared to approximately $2.8 million for the same period last year. As a result of lower revenue and increased operation activities, net loss reported for the nine months ended September 30, 2022, was increased to approximately $13 million or $0.35 per share compared with a net loss of approximately $6.7 million or $0.25 per share for the same period last year."
}